» Go to news main
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Posted by Angie Kinsman on
June 30, 2022
in
Nuclear Medicine
Dr. Steven Burrell has published a new article in Le Patient Magazine!
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Steven Burrell, MD, FRCPC Head of Nuclear Medicine QEII Health Sciences Centre
"When cancer has spread within the body the 2 main pillars of treatment are drugs such as chemotherapy which are administered internally and distribute throughout the body, and radiation which delivers tumour-destroying radiation from outside the body. However there is another approach..." Read more.
Recent News
- ‘A paradigm shift': A first in Canada, donor‑funded nuclear medicine scanner is helping QEII physicians assess and diagnose diseases with precision that wasn’t previously possible — all while tackling waitlists with greater efficiency
- New interventional radiology suite and hybrid operating room at the Halifax Infirmary
- Nova Scotia gets first‑in‑Canada relocatable MRI
- QEII welcomes the first GE StarGuide SPECT‑CT scanner in Canada.
- The first 68Ga‑PSMA PET scans in Atlantic Canada mark a new era in prostate cancer assessment
- Dr. David Volders awarded the Dr. Charles Lo Prize in Radiology Research
- Radiology Research Day 2024
- Program Administrator Award of Excellence